Skip to main content

Chugai Extends Deal for Use of Genedata Software

NEW YORK (GenomeWeb News) – Genedata today said that Japanese drug firm Chugai Pharmaceutical is extending its licensing agreement for use of the Genedata Expressionist software.

Chugai uses the product to streamline R&D processes and for enterprise-wide analysis and management of microarray data. Moving ahead, the company plans to use the software to analyze data for personalized medicine. In a statement, Junichi Muroya, of Chugai's bioinformatics department, said that in addition to day-to-day analysis, the company will explore using the software for next-generation sequencing.

Financial and other terms of the extension were not disclosed.

Chugai has used Genedata's software since at least 2007 to analyze high-throughput screening data.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.